Patients with systemic lupus erythematous (SLE) who take hydroxychloroquine do not have any differences in their corrected QT (QTc) intervals on electrocardiogram (EKG), even if they have chronic kidney disease (CKD), according to researchers reporting at the annual meeting of the American College of Rheumatology on Monday.
Lessons learned from antimalarial drug shortages during the COVID-19 pandemic: rheumatic disease patients in African and South-East Asia had difficulty obtaining antimalarials as compared to counterparts in the Americas and Europe. Shortages led to worse mental and physical health outcomes. Antimalarials did not protect patients from COVID-19.
Welcome to Overdrive, the podcast from Rheumatology Network. This week marks the start of the 2020 annual meeting of the American College of Rheumatology. Some of the studies we're covering include new therapies for lupus nephritis, the impact of COVID-19 on rheumatic disease patients, and pregnancy outcomes in ILD patients. Today, Dr. Fotios Koumpouras of the Yale School of Medicine, highlights some studies you won't want to miss at this year's meeting.
This week marks the start of the 2020 annual meeting of the American College of Rheumatology. Some of the studies we're covering include new therapies for lupus nephritis. Belimumab was shown recently to improve renal outcomes in lupus nephritis patients when added to standard of care. It will likely emerge as a significant treatment option, says Dr. Fotios Koumpouras, fellowship program director for rheumatology at Yale School of Medicine and a Rheumatology Network board member. Dr. Koumpouras breaks down his highlights in this interview.
Barriers to care for lupus patients has been well-document over the years. And, now, a consortium called the Addressing Lupus Pillars for Health Advancement (ALPHA) Project, has come up with a roadmap designed to resolve barriers to care.
The monoclonal antibody has built on its 18-month portfolio with sustained renal benefits for the at-need patient group.
New survey findings show the antimalarial drug's promotion for potential SARS-CoV-2 benefit early into the pandemic led to needing patients losing access.
In this week's news roundup from Rheumatology Network, we highlight more studies presented at Kidney Week, the American Society of Nephrology Kidney Week annual meeting which wrapped this week. Among the stories we covered, includes a possible new treatment for kidney transplant patients with gout, new hope in a new treatment for lupus nephritis and the American College of Rheumatology launches a project to treat underserved lupus patients. These and other headlines are included in this week's news roundup.
The American College of Rheumatology has launched a project designed to resolve inequities in care for patients with systemic lupus erythematosus, a condition that is two or three times more common among ethnic minorities. In this interview, S. Sam Lim, M.D., MPH, chair of ACR’s Collaborative Initiatives Special Committee, tells us more about the project.
Anti-inflammatory and immunosuppressive agents are the two primary classes of drugs used to treat lupus nephritis. Now, a new study shows that the addition of the monoclonal antibody belimumab to standard therapy may make a meaningful difference in this hard-to-treat patient population.
A possible new treatment for advanced lupus nephritis passes a phase two trial, according to a study presented at Kidney Week, the annual meeting of the American Society for Nephrology. The treatment, a CD20 antagonist called obinutuzumab, led to improvements in 41 percent of patients with lupus nephritis—a condition that affects one in 60 people with systemic lupus.
From COVID-19 presentations to emerging new therapies for chronic kidney disease, Dr. Bradley Marder, medical director of nephrology with Horizon Therapeutics, offers his take on the most memorable moments from the American Society for Nephrology/Kidney Week annual meeting which wrapped this week.
Treatments for lupus nephritis can cost patients over $50,000 a year, according to a study presented yesterday at the American Society of Nephrology Kidney Week annual meeting.
Belimumab (Benlysta, GlaxoSmithKline) can improve the kidney health of people with lupus nephritis, a new phase 3 clinical trial suggests.
Today, we talk with Dr. Richard Furie who is chief of rheumatology at Northwell Health in New York. Dr. Furie is the lead investigator of a study on lupus nephritis just published in the New England Journal of Medicine. Dr. Furie and colleagues from the Feinstein Institutes for Medical Research reported that belimumab with standard therapy has been shown to be an effective treatment for lupus nephritis. If the treatment is approved by the U.S. Food and Drug Administration, it would be the first of its kind for this condition. In this presentation, Dr. Furie tell us more.
Type I Interferon Inhibition Could Benefit Systemic Lupus Erythematosus
Cognitive impairment can be an ongoing issue for patients with rheumatic disease, such as lupus. A proper diagnosis includes a battery of tests, says Noa Shwartz, M.D., a physician-researcher with Albert Einstein College of Medicine in New York.
Simultaneous use of more than one drug is gaining traction as a treatment strategy for severe lupus symptoms, particularly in people with chronic kidney disease.
In today’s one-on-one interview, we talk with Dr. Richard Furie who is chief of rheumatology at Northwell Health in New York. Dr. Furie is the lead investigator of a study on lupus nephritis just published in the New England Journal of Medicine. Dr. Furie and colleagues from the Feinstein Institutes for Medical Research reported that belimumab with standard therapy has been shown to be an effective treatment for lupus nephritis. If the treatment is approved by the U.S. Food and Drug Administration, it would be the first of its kind for this condition. In this presentation, Dr. Furie tell us more.
Rheumatologists and OB-GYNs must communicate openly with each other and to patients with rheumatic diseases who are considering pregnancy.
The list of drugs suspected to cause drug-induced lupus erythematosus now includes metoclopramide hydrochloride, levothyroxine sodium, metronidazole hydrochloride and fexofenadine hydrochloride, according to a study published online this month in JAMA Dermatology.
covid-19
Researchers in China write in the current issue of The Lancet Rheumatology that patients with autoimmune rheumatic disease might be more susceptible to COVID-19 infections than the general population.
In this week’s news roundup from Rheumatology Network, we talk with Dr. Chrstine Anastasiou, a rheumatologist with the University of California San Francisco who recently published a study in Arthritis Care and Research that finds significant improvements in mortality for hospitalized patients in the U.S. with systemic lupus, but there remains a high mortality rate among blacks and Hispanics with SLE, and, now among Asian/Pacific Islanders with the condition. Learn more in this interview.
A few weeks after a camping trip in Connecticut, a 24-year-old woman went to her local urgent care center with flu-like symptoms of myalgia, arthralgias, headache, and fever. She reported having an annular lesion on her leg shortly after the trip. Can you diagnose this patient?
Dr. Richard Furie explains the link between systemic lupus erthematosus and COVID-19.
